130 related articles for article (PubMed ID: 31711656)
1. Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.
Mhawech-Fauceglia P; Izevbaye I; Spindler T; Wang G; Hwang H; Samrao D; Elishaev E; Maxwell GL; Lawrenson K; Darcy KM
Gynecol Oncol; 2020 Jan; 156(1):6-12. PubMed ID: 31711656
[TBL] [Abstract][Full Text] [Related]
2. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin-Proteasome Axis, Especially Ubiquitin-Specific Protease-17 (
Yildirim N; Kocal GC; Isik Z; Saatli B; Saygili U; Uysal T; Ulukus C; Koyuncuoglu M; Ellidokuz H; Basbinar Y
Reprod Sci; 2019 Jun; 26(6):794-805. PubMed ID: 30198418
[TBL] [Abstract][Full Text] [Related]
4. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
5. Not All Peritoneal Implants Are Created Equal.
Varghese A; Shih IM
Gynecol Oncol; 2020 Jan; 156(1):1-2. PubMed ID: 31954499
[No Abstract] [Full Text] [Related]
6. Ovarian serous borderline tumors with noninvasive and invasive peritoneal implants: A case report each.
Srinivasamurthy BC; Kulandai Velu AR; Krishnan N; Patil AS
J Cancer Res Ther; 2015; 11(3):646. PubMed ID: 26458602
[TBL] [Abstract][Full Text] [Related]
7. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas.
Bell KA; Smith Sehdev AE; Kurman RJ
Am J Surg Pathol; 2001 Apr; 25(4):419-32. PubMed ID: 11257616
[TBL] [Abstract][Full Text] [Related]
8. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological evaluation on ovarian serous borderline tumours and their implants].
Guo L; Lian L; Liu T
Zhonghua Fu Chan Ke Za Zhi; 1996 May; 31(5):287-90. PubMed ID: 9206182
[TBL] [Abstract][Full Text] [Related]
10. Calretinin, CD34, and alpha-smooth muscle actin in the identification of peritoneal invasive implants of serous borderline tumors of the ovary.
Lee ES; Leong AS; Kim YS; Lee JH; Kim I; Ahn GH; Kim HS; Chun YK
Mod Pathol; 2006 Mar; 19(3):364-72. PubMed ID: 16415795
[TBL] [Abstract][Full Text] [Related]
11. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
[TBL] [Abstract][Full Text] [Related]
12. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
[TBL] [Abstract][Full Text] [Related]
16. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome.
Auer K; Bachmayr-Heyda A; Aust S; Sukhbaatar N; Reiner AT; Grimm C; Horvat R; Zeillinger R; Pils D
Oncotarget; 2015 Jul; 6(19):17261-75. PubMed ID: 25991672
[TBL] [Abstract][Full Text] [Related]
18. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
[TBL] [Abstract][Full Text] [Related]
19. Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread.
Bachmayr-Heyda A; Auer K; Sukhbaatar N; Aust S; Deycmar S; Reiner AT; Polterauer S; Dekan S; Pils D
Oncotarget; 2016 Jun; 7(26):39640-39653. PubMed ID: 27172797
[TBL] [Abstract][Full Text] [Related]
20. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
